Growth hormone of Turner's syndrome: Beneficial effect on adult height

Ronald (Ron) Rosenfeld, K. M. Attie, J. Frane, J. A. Brasel, S. Burstein, J. F. Cara, S. Chernausek, R. W. Gotlin, J. Kuntze, B. M. Lippe, C. P. Mahoney, W. V. Moore, P. Saenger, A. J. Johanson

Research output: Contribution to journalArticle

227 Citations (Scopus)

Abstract

Objective: To carry out a multicenter, prospective, randomized trial of human growth hormone (GH), alone or in combination with oxandrolone (ox), in patients with Turner's syndrome (TS). Methods: In an initial phase lasting 12 to 24 months, 70 girls with TS, verified by karyotype, were randomly assigned to one of four groups: (1) observation, (2) OX. (3) GH, or (4) GH plus OX. After completion of the first phase, group 3 subjects continued to receive GH only. All other subjects were treated with GH plus OX. Subjects were followed up until attainment of adult height and/or cessation of treatment. Data from this trial were compared with growth characteristics of 25 American historical subjects with TS (matched for age, height, parental target height, and karyotype) who never received either GH or androgens Results: Of the 70 subjects enrolled, 60 completed the clinical trial. The 17 subjects receiving GH alone all completed the trial and reached a height of 150.4 ± 5.5 cm (mean ± SD), 8.4 ± 4.5 cm taller than their mean projected adult height at enrollment (96% confidence interval [CI]: 6.3 to 10.6 cm). The 43 subjects receiving GH plus OX attained a mean height of 152.1 ± 5.9 cm, 10.3 ± 4.7 cm railer than their mean projected adult height (95% CI: 8.9 to 11.7 cm). The historical control subjects had a mean adult height of 144.2 ± 6.0 cm, precisely matching their original projected adult height of 144.2 ± 6.1 cm. Conclusions: GH, either alone or in combination with OX, is capable of stimulating short-term growth and augmenting adult height in girls with TS. With early diagnosis and initiation of treatment adult height of more than 150 cm is a reasonable goal for most girls with TS.

Original languageEnglish (US)
Pages (from-to)319-324
Number of pages6
JournalJournal of Pediatrics
Volume132
Issue number2
DOIs
StatePublished - 1998

Fingerprint

Turner Syndrome
Growth Hormone
Karyotype
Oxandrolone
Confidence Intervals
Withholding Treatment
Human Growth Hormone
Growth
Androgens
Early Diagnosis
Parents
Observation
Clinical Trials

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Rosenfeld, R. R., Attie, K. M., Frane, J., Brasel, J. A., Burstein, S., Cara, J. F., ... Johanson, A. J. (1998). Growth hormone of Turner's syndrome: Beneficial effect on adult height. Journal of Pediatrics, 132(2), 319-324. https://doi.org/10.1016/S0022-3476(98)70452-4

Growth hormone of Turner's syndrome : Beneficial effect on adult height. / Rosenfeld, Ronald (Ron); Attie, K. M.; Frane, J.; Brasel, J. A.; Burstein, S.; Cara, J. F.; Chernausek, S.; Gotlin, R. W.; Kuntze, J.; Lippe, B. M.; Mahoney, C. P.; Moore, W. V.; Saenger, P.; Johanson, A. J.

In: Journal of Pediatrics, Vol. 132, No. 2, 1998, p. 319-324.

Research output: Contribution to journalArticle

Rosenfeld, RR, Attie, KM, Frane, J, Brasel, JA, Burstein, S, Cara, JF, Chernausek, S, Gotlin, RW, Kuntze, J, Lippe, BM, Mahoney, CP, Moore, WV, Saenger, P & Johanson, AJ 1998, 'Growth hormone of Turner's syndrome: Beneficial effect on adult height', Journal of Pediatrics, vol. 132, no. 2, pp. 319-324. https://doi.org/10.1016/S0022-3476(98)70452-4
Rosenfeld RR, Attie KM, Frane J, Brasel JA, Burstein S, Cara JF et al. Growth hormone of Turner's syndrome: Beneficial effect on adult height. Journal of Pediatrics. 1998;132(2):319-324. https://doi.org/10.1016/S0022-3476(98)70452-4
Rosenfeld, Ronald (Ron) ; Attie, K. M. ; Frane, J. ; Brasel, J. A. ; Burstein, S. ; Cara, J. F. ; Chernausek, S. ; Gotlin, R. W. ; Kuntze, J. ; Lippe, B. M. ; Mahoney, C. P. ; Moore, W. V. ; Saenger, P. ; Johanson, A. J. / Growth hormone of Turner's syndrome : Beneficial effect on adult height. In: Journal of Pediatrics. 1998 ; Vol. 132, No. 2. pp. 319-324.
@article{019cd72c7f9e4af092005626f0ebd19a,
title = "Growth hormone of Turner's syndrome: Beneficial effect on adult height",
abstract = "Objective: To carry out a multicenter, prospective, randomized trial of human growth hormone (GH), alone or in combination with oxandrolone (ox), in patients with Turner's syndrome (TS). Methods: In an initial phase lasting 12 to 24 months, 70 girls with TS, verified by karyotype, were randomly assigned to one of four groups: (1) observation, (2) OX. (3) GH, or (4) GH plus OX. After completion of the first phase, group 3 subjects continued to receive GH only. All other subjects were treated with GH plus OX. Subjects were followed up until attainment of adult height and/or cessation of treatment. Data from this trial were compared with growth characteristics of 25 American historical subjects with TS (matched for age, height, parental target height, and karyotype) who never received either GH or androgens Results: Of the 70 subjects enrolled, 60 completed the clinical trial. The 17 subjects receiving GH alone all completed the trial and reached a height of 150.4 ± 5.5 cm (mean ± SD), 8.4 ± 4.5 cm taller than their mean projected adult height at enrollment (96{\%} confidence interval [CI]: 6.3 to 10.6 cm). The 43 subjects receiving GH plus OX attained a mean height of 152.1 ± 5.9 cm, 10.3 ± 4.7 cm railer than their mean projected adult height (95{\%} CI: 8.9 to 11.7 cm). The historical control subjects had a mean adult height of 144.2 ± 6.0 cm, precisely matching their original projected adult height of 144.2 ± 6.1 cm. Conclusions: GH, either alone or in combination with OX, is capable of stimulating short-term growth and augmenting adult height in girls with TS. With early diagnosis and initiation of treatment adult height of more than 150 cm is a reasonable goal for most girls with TS.",
author = "Rosenfeld, {Ronald (Ron)} and Attie, {K. M.} and J. Frane and Brasel, {J. A.} and S. Burstein and Cara, {J. F.} and S. Chernausek and Gotlin, {R. W.} and J. Kuntze and Lippe, {B. M.} and Mahoney, {C. P.} and Moore, {W. V.} and P. Saenger and Johanson, {A. J.}",
year = "1998",
doi = "10.1016/S0022-3476(98)70452-4",
language = "English (US)",
volume = "132",
pages = "319--324",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Growth hormone of Turner's syndrome

T2 - Beneficial effect on adult height

AU - Rosenfeld, Ronald (Ron)

AU - Attie, K. M.

AU - Frane, J.

AU - Brasel, J. A.

AU - Burstein, S.

AU - Cara, J. F.

AU - Chernausek, S.

AU - Gotlin, R. W.

AU - Kuntze, J.

AU - Lippe, B. M.

AU - Mahoney, C. P.

AU - Moore, W. V.

AU - Saenger, P.

AU - Johanson, A. J.

PY - 1998

Y1 - 1998

N2 - Objective: To carry out a multicenter, prospective, randomized trial of human growth hormone (GH), alone or in combination with oxandrolone (ox), in patients with Turner's syndrome (TS). Methods: In an initial phase lasting 12 to 24 months, 70 girls with TS, verified by karyotype, were randomly assigned to one of four groups: (1) observation, (2) OX. (3) GH, or (4) GH plus OX. After completion of the first phase, group 3 subjects continued to receive GH only. All other subjects were treated with GH plus OX. Subjects were followed up until attainment of adult height and/or cessation of treatment. Data from this trial were compared with growth characteristics of 25 American historical subjects with TS (matched for age, height, parental target height, and karyotype) who never received either GH or androgens Results: Of the 70 subjects enrolled, 60 completed the clinical trial. The 17 subjects receiving GH alone all completed the trial and reached a height of 150.4 ± 5.5 cm (mean ± SD), 8.4 ± 4.5 cm taller than their mean projected adult height at enrollment (96% confidence interval [CI]: 6.3 to 10.6 cm). The 43 subjects receiving GH plus OX attained a mean height of 152.1 ± 5.9 cm, 10.3 ± 4.7 cm railer than their mean projected adult height (95% CI: 8.9 to 11.7 cm). The historical control subjects had a mean adult height of 144.2 ± 6.0 cm, precisely matching their original projected adult height of 144.2 ± 6.1 cm. Conclusions: GH, either alone or in combination with OX, is capable of stimulating short-term growth and augmenting adult height in girls with TS. With early diagnosis and initiation of treatment adult height of more than 150 cm is a reasonable goal for most girls with TS.

AB - Objective: To carry out a multicenter, prospective, randomized trial of human growth hormone (GH), alone or in combination with oxandrolone (ox), in patients with Turner's syndrome (TS). Methods: In an initial phase lasting 12 to 24 months, 70 girls with TS, verified by karyotype, were randomly assigned to one of four groups: (1) observation, (2) OX. (3) GH, or (4) GH plus OX. After completion of the first phase, group 3 subjects continued to receive GH only. All other subjects were treated with GH plus OX. Subjects were followed up until attainment of adult height and/or cessation of treatment. Data from this trial were compared with growth characteristics of 25 American historical subjects with TS (matched for age, height, parental target height, and karyotype) who never received either GH or androgens Results: Of the 70 subjects enrolled, 60 completed the clinical trial. The 17 subjects receiving GH alone all completed the trial and reached a height of 150.4 ± 5.5 cm (mean ± SD), 8.4 ± 4.5 cm taller than their mean projected adult height at enrollment (96% confidence interval [CI]: 6.3 to 10.6 cm). The 43 subjects receiving GH plus OX attained a mean height of 152.1 ± 5.9 cm, 10.3 ± 4.7 cm railer than their mean projected adult height (95% CI: 8.9 to 11.7 cm). The historical control subjects had a mean adult height of 144.2 ± 6.0 cm, precisely matching their original projected adult height of 144.2 ± 6.1 cm. Conclusions: GH, either alone or in combination with OX, is capable of stimulating short-term growth and augmenting adult height in girls with TS. With early diagnosis and initiation of treatment adult height of more than 150 cm is a reasonable goal for most girls with TS.

UR - http://www.scopus.com/inward/record.url?scp=0031991527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031991527&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(98)70452-4

DO - 10.1016/S0022-3476(98)70452-4

M3 - Article

C2 - 9506648

AN - SCOPUS:0031991527

VL - 132

SP - 319

EP - 324

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 2

ER -